inclusion criteria: 1. male or non-pregnant female age ≥18 years, inclusive 2. subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization 4. radiographic evidence of bilateral infiltrates 5. subject requires high-flow oxygen or meets clinical classification for ards 6. elevated serum crp or ferritin 7. subjects who have been treated with convalescent plasma (cp) prior to enrollment are eligible if the subject continues to meet all inclusion criteria at screening 8. the use of investigational anti-viral treatment (e.g., remdesivir) is allowed if the subject continues to meet all inclusion criteria at screening additional inclusion criteria are detailed in the protocol

inclusion criteria: 1. male or non-pregnant female age ≥18 years, inclusive 2. subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization 4. radiographic evidence of bilateral infiltrates 5. subject requires high-flow oxygen or meets clinical classification for ards 6. elevated serum crp or ferritin 7. subjects who have been treated with convalescent plasma (cp) prior to enrollment are eligible if the subject continues to meet all inclusion criteria at screening 8. the use of investigational anti-viral treatment (e.g., remdesivir) is allowed if the subject continues to meet all inclusion criteria at screening additional inclusion criteria are detailed in the protocol

inclusion criteria: male or non-pregnant female age ≥18 years, inclusive subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization radiographic evidence of bilateral infiltrates subject requires high-flow oxygen or meets clinical classification for ards elevated serum crp or ferritin subjects who have been treated with convalescent plasma (cp) prior to enrollment are eligible if the subject continues to meet all inclusion criteria at screening the use of investigational anti-viral treatment (e.g., remdesivir) is allowed if the subject continues to meet all inclusion criteria at screening additional inclusion criteria are detailed in the protocol

inclusion criteria: male or non-pregnant female age ≥18 years, inclusive subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization radiographic evidence of bilateral infiltrates subject requires high-flow oxygen or meets clinical classification for ards elevated serum crp or ferritin subjects who have been treated with convalescent plasma (cp) prior to enrollment are eligible if the subject continues to meet all inclusion criteria at screening the use of investigational anti-viral treatment (e.g., remdesivir) is allowed if the subject continues to meet all inclusion criteria at screening additional inclusion criteria are detailed in the protocol

inclusion criteria: male or non-pregnant female age ≥18 years, inclusive subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization radiographic evidence of bilateral infiltrates subject requires high-flow oxygen or meets clinical classification for ards elevated serum crp or ferritin subjects who have been treated with convalescent plasma prior to enrollment are eligible if the subject continues to meet all entry criteria at screening the use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine) is allowed during the study additional inclusion criteria are detailed in the protocol

inclusion criteria: male or non-pregnant female age ≥18 years, inclusive subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization radiographic evidence of bilateral infiltrates subject requires high-flow oxygen or meets clinical classification for ards elevated serum crp or ferritin subjects who have been treated with convalescent plasma prior to enrollment are eligible if the subject continues to meet all entry criteria at screening the use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine) is allowed during the study additional inclusion criteria are detailed in the protocol

inclusion criteria: 1. male or non-pregnant female age ≥18 years, inclusive 2. subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization 4. radiographic evidence of bilateral infiltrates 5. subject requires high-flow oxygen or meets clinical classification for ards 6. elevated serum crp or ferritin 7. subjects who have been treated with convalescent plasma prior to enrollment are eligible if the subject continues to meet all entry criteria at screening 8. the use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine) is allowed during the study additional inclusion criteria are detailed in the protocol

inclusion criteria: 1. male or non-pregnant female age ≥18 years, inclusive 2. subject (or legally authorized representative) is able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form 3. has laboratory-confirmed sars-cov-2 infection as determined by pcr or other approved clinical testing prior to randomization 4. radiographic evidence of bilateral infiltrates 5. subject requires high-flow oxygen or meets clinical classification for ards 6. elevated serum crp or ferritin 7. subjects who have been treated with convalescent plasma prior to enrollment are eligible if the subject continues to meet all entry criteria at screening 8. the use of investigational antiviral treatments (e.g., remdesivir, hydroxychloroquine) is allowed during the study additional inclusion criteria are detailed in the protocol